Enrique
Aranda Aguilar
Publications by the researcher in collaboration with Enrique Aranda Aguilar (17)
2023
-
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
Biomedicine and Pharmacotherapy, Vol. 159
-
Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials
Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230
2022
-
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)
European Journal of Cancer, Vol. 177, pp. 154-163
-
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
British Journal of Cancer, Vol. 126, Núm. 6, pp. 874-880
-
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132
2021
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
-
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study
ESMO open, Vol. 6, Núm. 2, pp. 100062
2019
-
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
British Journal of Cancer, Vol. 121, Núm. 5, pp. 378-383
-
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy
Annals of Oncology, Vol. 30, Núm. 3, pp. 439-446
2018
-
A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer
Clinical Colorectal Cancer, Vol. 17, Núm. 2, pp. e323-e329
-
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): A pharmacogenetic-based randomized phase II trial
Annals of Oncology, Vol. 29, Núm. 2, pp. 439-444
2017
-
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)
European Journal of Cancer, Vol. 81, pp. 191-202
2015
-
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02
Cancer Chemotherapy and Pharmacology, Vol. 75, Núm. 2, pp. 319-324
2013
-
Bevacizumab plus chemotherapy continued beyond first progression in patients withmetastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
Annals of Oncology, Vol. 24, Núm. 9, pp. 2342-2349
2012
-
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: Clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD group study
Oncologist, Vol. 17, Núm. 3, pp. 339-345
-
Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A phase ii study of the Spanish cooperative group for the treatment of digestive tumors
Clinical Colorectal Cancer, Vol. 11, Núm. 3, pp. 200-206
-
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: Relationship between skin rash and survival (Pantar study)
Annals of Oncology, Vol. 23, Núm. 7, pp. 1919-1925